sEH-IN-21 is an orally active inhibitor of sEH, exhibiting IC50 values of 0.1 nM for both hsEH and msEH. It significantly suppresses the NF-κB signaling pathway. sEH-IN-21 demonstrates potent anti-inflammatory activity by reducing IL-6 and TNF-α release and maintaining intestinal barrier integrity. It is applicable in research on inflammatory bowel disease (IBD).

sEH (human):0.1 nM

sEH-IN-21 (Compound A1) exhibits good metabolic stability in mouse liver microsomes, with a half-life of 13.51 minutes, and has a plasma protein binding rate of 96.2%.

sEH-IN-21 (Compound A1), administered orally at doses of 25-100 mg/kg for 10 days, exhibits anti-inflammatory properties by enhancing intestinal mucosal barrier function, thereby reducing the severity of DSS-induced acute colitis in mice. Additionally, sEH-IN-21 is well-tolerated and demonstrates high safety at a dose of 1 g/kg over a 7-day intragastric administration in mice.